BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qi X, Yang M, Ma L, Sauer M, Avella D, Kaifi JT, Bryan J, Cheng K, Staveley-O'Carroll KF, Kimchi ET, Li G. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. J Immunother Cancer 2020;8:e001038. [PMID: 33115942 DOI: 10.1136/jitc-2020-001038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Füchsl F, Krackhardt AM. Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers 2022;14:4192. [DOI: 10.3390/cancers14174192] [Reference Citation Analysis]
2 Zhang G, Yun Y, Lin C, Li H. Predictive Value of MRI with Serum Lectin-Reactive Alpha-Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation. Evid Based Complement Alternat Med 2022;2022:5132135. [PMID: 35911145 DOI: 10.1155/2022/5132135] [Reference Citation Analysis]
3 Pu Q, Yu L, Wang X, Yan H, Xie Y, Du J, Yang Z. . OTT 2022;Volume 15:925-40. [DOI: 10.2147/ott.s373631] [Reference Citation Analysis]
4 Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 2022;10:e004205. [PMID: 35710293 DOI: 10.1136/jitc-2021-004205] [Reference Citation Analysis]
5 Luo Z, Yao X, Li M, Fang, Fei Y, Cheng Z, Xu Y, Zhu B. Modulating tumor physical microenvironment for fueling CAR-T cell therapy. Adv Drug Deliv Rev 2022;185:114301. [PMID: 35439570 DOI: 10.1016/j.addr.2022.114301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Guo H, Huang J, Tan Y, Wu W, Huang T, Zhang N, Chen S, Zhang C, Xie X, Shuai X, Xu M. Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. Nano Today 2022;43:101425. [DOI: 10.1016/j.nantod.2022.101425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Qi X, Wu F, Kim SH, Kaifi JT, Kimchi ET, Snyder H, Illendula A, Fox T, Kester M, Staveley-O'Carroll KF, Li G. Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer. FASEB J 2022;36:e22250. [PMID: 35294071 DOI: 10.1096/fj.202101707R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Liu X, Luo J, Zhang L, Yang F, Peng D. SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization. Clin Res Hepatol Gastroenterol 2022;:101897. [PMID: 35240318 DOI: 10.1016/j.clinre.2022.101897] [Reference Citation Analysis]
9 Bian M, Fan R, Yang Z, Chen Y, Xu Z, Lu Y, Liu W. Pt(II)-NHC Complex Induces ROS-ERS-Related DAMP Balance to Harness Immunogenic Cell Death in Hepatocellular Carcinoma. J Med Chem 2022. [PMID: 35025488 DOI: 10.1021/acs.jmedchem.1c01248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
10 Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, Jin C. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Front Immunol 2021;12:792781. [PMID: 34975896 DOI: 10.3389/fimmu.2021.792781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhou J, Jiang Y, Huang Y, Wang Q, Kaifi JT, Kimchi ET, Chabu CY, Liu Z, Joshi T, Li G. Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Transl Oncol 2021;15:101262. [PMID: 34768100 DOI: 10.1016/j.tranon.2021.101262] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Li Z, Li Q, Wang X, Chen W, Jin X, Liu X, Ye F, Dai Z, Zheng X, Li P, Sun C, Liu X, Zhang Q, Luo H, Liu R. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2021. [PMID: 34655179 DOI: 10.1002/cam4.4350] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Yang M, Kimchi ET, Staveley-O'Carroll KF, Li G. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. Int J Mol Sci 2021;22:11037. [PMID: 34681695 DOI: 10.3390/ijms222011037] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
14 Li M, Hao B, Zhang M, Reiter RJ, Lin S, Zheng T, Chen X, Ren Y, Yue L, Abay B, Chen G, Xu X, Shi Y, Fan L. Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development. Signal Transduct Target Ther 2021;6:330. [PMID: 34471091 DOI: 10.1038/s41392-021-00745-7] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
15 Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021;11:5365-86. [PMID: 33859752 DOI: 10.7150/thno.58390] [Cited by in Crossref: 45] [Cited by in F6Publishing: 53] [Article Influence: 45.0] [Reference Citation Analysis]